This study reports the effects of 1% topical Brinzolamide on macular oedema in glaucomatous pseudophakic eyes which have previously sustained vitrectomy and peeling of the internal limiting membrane (ILM).

Conditions:

In seven cases of glaucomatous pseudophakic eyes with previous vitrectomy and ILM peeling, chronic macular oedema occurred . There was not a good tonometric compensation with ß-blockers and no response to topical (NSAIDs) in each case. Steroids could not be used without the risk that the glaucoma might become worse.

Methods:

With the aim of achieving a good tonometric control, therapy was shifted from ß-blockers alone to topical Brinzolamide 1% in association with ß-blockers. The patients who did not show any results after 1 month of therapy were accepted for treatment by Acetazolamide (250 tablets) and intravitreal injection of Bevacizumab. Four of these patients showed a reduction in macular thickness; the CMT was 383 µ (±34) at baseline decreasing to 250 µ (±25) by the third month. They also experienced a reduction in metamorphopsia on the Amsler grid and improvement in visual acuity, 6 ETDRS letters (±3).

Effectiveness:

Brinzolamide 1% showed promising results in a good percentage of this glaucomatous pseudophakic patients with previous ILM peeling.